The Latest Osteoarthritis Research, Explained

A clear review of where osteoarthritis research actually stands — what's genuinely new, what's still confined to the laboratory, and what it means for anyone living with the condition now.

Last reviewed: July 2026

This has been one of the most eventful periods in osteoarthritis research in decades. Headlines have promised regrown cartilage and reversed arthritis. Meanwhile, a major review quietly questioned whether the single most-recommended treatment in the world works as well as everyone assumed.

Both stories are real. Neither is quite what the headlines suggest. Here's where the science stands.

What You'll Find Here

• The cartilage-regeneration research behind the headlines — and what stage it has actually reached

• The review that challenged exercise as first-line treatment

• A walking-technique trial with results that surprised its own researchers

• A newer non-surgical procedure for knee pain

• What patients can realistically use today, and one area worth watching

Cartilage Regeneration Has Moved From "Impossible" to "Plausible"

For decades, the defining fact of osteoarthritis has been that adults don't regrow articular cartilage. The tissue has almost no blood supply, which severely limits its ability to heal itself.

Recent work from Stanford Medicine challenges that assumption. By blocking an ageing-related protein called 15-PGDH, researchers restored lost cartilage in old mice and helped prevent arthritis after knee injuries. Human cartilage samples — collected during knee replacement surgeries — began producing new, functional cartilage when exposed to the treatment. The researchers suggest that, if it works in people, the approach could eventually reduce the need for knee and hip replacements, and an oral version is already being tested in clinical trials for age-related muscle weakness.

Separately, researchers at the University of Colorado Boulder, CU Anschutz and Colorado State University have reported experimental treatments that appeared to regenerate damaged joints in animal studies — with a single injection restoring arthritic joints to a healthy state within weeks.

The caveat that matters: these are animal studies and laboratory tissue samples, not treatments a doctor can offer. No treatment widely available today regrows knee cartilage, and the gap between a laboratory result and a prescribable therapy is measured in years of clinical trials, regulatory review and manufacturing. The direction of travel is hopeful. The timeline is not short.

The Exercise Consensus Was Challenged

This is the finding most likely to surprise patients and clinicians alike.

Exercise has been the near-universal first-line recommendation for osteoarthritis, in every major guideline. Then an umbrella systematic review published in RMD Open concluded that the effectiveness of exercise therapy for easing osteoarthritis symptoms is likely minimal, short-lived, and possibly no better than no treatment at all — findings that question its universal promotion as first-line treatment. Pooled together, exercise was linked to small and short-lived reductions in knee osteoarthritis pain compared with placebo or no treatment, and produced outcomes broadly similar to patient education, manual therapy, painkillers, steroid or hyaluronic acid injections, and keyhole surgery.

Read that carefully, because it is not "don't exercise." The researchers are explicit: exercise offers other health benefits beyond joint pain relief, and they recommend shared decision-making that weighs its effects alongside safety, low cost, and the alternatives. The lead author's framing was that the relief exercise provides appears small and probably doesn't last long, meaning ongoing exercise may be needed simply to maintain the modest benefit. A response in Nature Reviews Rheumatology summarised the counter-position in its title: small — but relevant.

Where that leaves things: exercise remains safe, broadly beneficial, and still recommended. What's under debate is how much it does for pain specifically, and for whom. That's a healthy scientific argument, not a reversal.

Not All Exercise Is Equal

A large review in The BMJ helped answer the obvious follow-up question — which exercise? Drawing on over 200 studies and more than 15,000 participants, it found aerobic activity — walking, cycling, swimming — offered the strongest evidence for pain relief and mobility in knee osteoarthritis, outperforming other exercise types across short- and long-term outcomes. All forms were safe, but the authors recommend making aerobic activity the foundation.

Read alongside the RMD Open review, a reasonable synthesis emerges: exercise may not be the panacea it's sometimes presented as, but if you're going to do it, aerobic movement has the best case behind it.

How You Walk May Matter More Than Expected

One of the more elegant recent findings came from a randomised controlled trial in The Lancet Rheumatology. Researchers from the University of Utah, NYU and Stanford tested personalised gait retraining — adjusting the angle of a patient's foot during walking. Over a year, participants reported pain relief comparable to medication, and showed slower cartilage deterioration on MRI than a placebo group.

The operative word is personalised. Earlier trials prescribed the same walking change to everyone, which meant some participants didn't reduce their joint loading — and some increased it. This trial tailored the adjustment to each individual's gait, which the researchers believe explains the benefit seen in both pain and cartilage. It is not a "turn your toes in" instruction — the wrong adjustment could increase stress on the knee, which is why the method still needs simplifying before it can be used widely in clinics.

A Newer Non-Surgical Procedure for Knee Pain

Research published in Radiology reported that genicular artery embolisation — a minimally invasive procedure that blocks abnormal blood vessels around the knee — may offer long-lasting relief for people with osteoarthritis. It's an interventional-radiology approach rather than a drug or an operation, and it points to a growing middle ground between conservative management and joint replacement.

Where Each Development Actually Stands

Scroll right to see the full table on mobile →

What Patients Can Use Today

Stepping back from the laboratory, the practical picture for someone with osteoarthritis now is more modest, and worth stating plainly.

Movement and weight management remain the foundation of care, with the nuances above: favour aerobic activity, hold realistic expectations, and keep going, since the benefits fade when you stop. Physiotherapy strengthens the muscles supporting the joint, which reduces the load it carries. Topical anti-inflammatories are recommended ahead of oral ones for knee and hand osteoarthritis by both the American College of Rheumatology and the UK's NICE, given a gentler safety profile. Injections — corticosteroid, hyaluronic acid, platelet-rich plasma — ease symptoms or buy time, with evidence that varies by type. Bracing can offload a joint worn unevenly. Joint replacement remains highly effective when a joint reaches end stage.

What unites almost all of it: these approaches manage symptoms or redistribute load. Very few act on the joint tissue itself — which brings us to the problem underneath the whole field.

The Area Worth Watching: Delivery

Nearly every difficulty in treating osteoarthritis traces back to one anatomical fact. Cartilage has almost no blood supply. It heals poorly on its own, and anything carried by the bloodstream — including swallowed supplements — struggles to reach it in meaningful quantities. One plausible explanation for the inconsistent results seen with oral glucosamine is precisely this: the compound is a genuine constituent of cartilage, but the delivery route is a poor match for the target tissue.

So a distinct line of research asks a different question: not what to deliver, but how. If the bloodstream is an inefficient route to cartilage, is there a better one?

One approach has come out of Nanyang Technological University, working with A*STAR, Singapore's national research agency: a micellar system engineered to improve transdermal delivery of glucosamine as an alternative to oral administration. In an independent, peer-reviewed knee osteoarthritis trial, a micellar transdermal glucosamine cream was associated with an average 61% increase in joint space width over 12 weeks — an indirect measure of cartilage thickness. Separately, absorption research has reported substantially greater glucosamine uptake by this transdermal route than by the oral form.

The findings should be read as any single study is read: the trial is one study of modest size, joint space width is an indirect marker rather than a direct image of cartilage, and independent replication would strengthen confidence considerably. It is emphatically not the cartilage regeneration described in the Stanford work — nothing available today rebuilds a worn joint. But in a field where most structural results still come from animal models, a structural result in humans is notable, and delivery science is an area to watch. We examine that evidence, and what it does and doesn't support, in our review of whether osteoarthritis can be reversed.

What Isn't Covered Here

This review focuses on peer-reviewed research rather than every therapy promoted for osteoarthritis. Many interventions marketed online — including several popular supplements, devices, and stem-cell offerings — either lack robust clinical evidence or show mixed results across studies. Their absence here reflects the state of the published evidence rather than a judgement on any individual product.

What This All Means

The future looks better than the present. Cartilage regeneration is moving from science fiction toward science — but not into clinics this year. Anyone offering cartilage regrowth today is ahead of the evidence.

The fundamentals are being refined, not discarded. Exercise is under legitimate scrutiny, but the sensible response isn't to stop moving. It's to hold realistic expectations, favour aerobic activity, and stay consistent.

Delivery is the quiet frontier. Getting anything into a tissue with no blood supply is one of the field's genuinely hard problems — and it's where several of the more promising avenues, from regeneration to transdermal routes, are converging.

Frequently Asked Questions

Has anyone regrown cartilage?

In laboratory and animal research, yes — Stanford researchers restored cartilage in aged mice by blocking a protein called 15-PGDH, and human cartilage samples produced new tissue in the laboratory. But no treatment available to patients regrows cartilage today. These findings remain years from clinical use, and current care focuses on managing symptoms and protecting the joint that remains.

Is exercise still recommended for osteoarthritis?

Yes, though it has come under healthy scrutiny. An umbrella review found the pain benefits smaller and shorter-lived than assumed, prompting debate about exercise as universal first-line treatment. Exercise remains safe and carries broad health benefits, and a large BMJ review found aerobic activity — walking, cycling, swimming — the best-evidenced type. The nuance is realistic expectations, not avoidance.

What is the most promising new osteoarthritis treatment?

Scientifically, 15-PGDH inhibition, which produced cartilage regeneration in animal and laboratory work — though it is years from approval. Closer to patients, personalised gait retraining showed pain relief comparable to medication alongside slower cartilage loss, and genicular artery embolisation is providing durable relief in some centres. Promising is not the same as available.

Why is cartilage so difficult to treat?

Cartilage has almost no blood supply. That single fact explains most of the difficulty: the tissue heals poorly on its own, and anything carried by the bloodstream — including swallowed supplements — struggles to reach it in meaningful amounts. Much of the current research effort targets this problem directly, whether by regenerating the tissue or by finding better routes into it.

Can a topical treatment do more than ease pain?

Topical anti-inflammatories are recommended ahead of oral ones for knee and hand osteoarthritis by both the ACR and NICE, and act on the tissues around the joint. A separate line of research explores transdermal delivery — engineering carriers to improve absorption of a compound through the skin rather than through the gut. One micellar system, developed at NTU with A*STAR, was evaluated in a peer-reviewed knee trial that reported an increase in joint space width: a limited but notable human result that warrants independent replication.

Further Reading

• Can Osteoarthritis Be Reversed? What the Cartilage Evidence Shows

• Alternatives to Knee Replacement: What Actually Works Before You Go Under

• How to Support Knee Cartilage

• Osteoarthritis Treatment Options Compared

References

1. Stanford Medicine. Blocking 15-PGDH restores cartilage in aged mice and stimulates human cartilage tissue. https://www.sciencedaily.com/releases/2026/06/260612021604.htm

2. Schleimer T, et al. Effectiveness of exercise therapy for osteoarthritis: an overview of systematic reviews and randomised controlled trials. RMD Open, 2026;12(1):e006275. https://pubmed.ncbi.nlm.nih.gov/41702669/

3. Bierma-Zeinstra S, Runhaar J. Small but relevant effects of exercise therapy in osteoarthritis. Nature Reviews Rheumatology, 2026. https://www.nature.com/articles/s41584-026-01377-3

4. Aerobic exercise and knee osteoarthritis: systematic review and network meta-analysis. The BMJ. https://www.sciencedaily.com/releases/2025/10/251019120521.htm

5. Uhlrich SD, et al. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial. The Lancet Rheumatology, 2025. DOI: 10.1016/S2665-9913(25)00151-1

6. Fleckenstein FN, et al. Genicular Artery Embolization Using Rapidly Resorbable Gelatin-based Microspheres for Osteoarthritis-related Knee Pain. Radiology, 2026;319(3). DOI: 10.1148/radiol.253312

7. University of Colorado Boulder. Regenerative injection therapies for osteoarthritis in animal models. https://www.sciencedaily.com/releases/2026/06/260619101356.htm

8. Kolasinski SL, et al. 2019 ACR/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020;72(2):220–233. https://pubmed.ncbi.nlm.nih.gov/31908163/

9. NICE. Osteoarthritis in over 16s: diagnosis and management (NG226). https://www.nice.org.uk/guidance/ng226

10. Onigbinde AT, et al. Symptoms-modifying effects of electromotive administration of glucosamine sulphate among patients with knee osteoarthritis. Hong Kong Physiotherapy Journal, 2018;38(1):63–75. https://pubmed.ncbi.nlm.nih.gov/30930580/

11. Liang K, et al. Micellar transdermal delivery — comparative glucosamine blood absorption, micellar cream vs oral (Supplementary Figure S7). BMC Research Notes, 2016;9:254. https://link.springer.com/article/10.1186/s13104-016-2047-x

This review is updated as significant osteoarthritis research is published.

Naomi Kim has over 7 years of experience in healthcare, including founding a health startup. She contributes to Umicellar, an evidence-based platform reviewing emerging research in joint health and healthy ageing.

Medical Disclaimer: This article summarises published research for general information and is not medical advice. Research described at preclinical or early-trial stage is not available as treatment. Decisions about osteoarthritis management should be made with your doctor.